JP2005530736A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530736A5
JP2005530736A5 JP2003585730A JP2003585730A JP2005530736A5 JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5 JP 2003585730 A JP2003585730 A JP 2003585730A JP 2003585730 A JP2003585730 A JP 2003585730A JP 2005530736 A5 JP2005530736 A5 JP 2005530736A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
optionally substituted
amount
beta blocker
esmolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/012043 external-priority patent/WO2003088978A1/en
Publication of JP2005530736A publication Critical patent/JP2005530736A/ja
Publication of JP2005530736A5 publication Critical patent/JP2005530736A5/ja
Pending legal-status Critical Current

Links

JP2003585730A 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法 Pending JP2005530736A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376602P 2002-04-18 2002-04-18
PCT/US2003/012043 WO2003088978A1 (en) 2002-04-18 2003-04-18 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (2)

Publication Number Publication Date
JP2005530736A JP2005530736A (ja) 2005-10-13
JP2005530736A5 true JP2005530736A5 (cg-RX-API-DMAC10.html) 2006-06-01

Family

ID=29251078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585730A Pending JP2005530736A (ja) 2002-04-18 2003-04-18 ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法

Country Status (17)

Country Link
US (3) US7005425B2 (cg-RX-API-DMAC10.html)
EP (1) EP1494685B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005530736A (cg-RX-API-DMAC10.html)
KR (1) KR20040106354A (cg-RX-API-DMAC10.html)
CN (2) CN101385738A (cg-RX-API-DMAC10.html)
AT (1) ATE418991T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003235466C1 (cg-RX-API-DMAC10.html)
CA (1) CA2482928A1 (cg-RX-API-DMAC10.html)
DE (1) DE60325572D1 (cg-RX-API-DMAC10.html)
ES (1) ES2318129T3 (cg-RX-API-DMAC10.html)
IL (1) IL164652A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04010285A (cg-RX-API-DMAC10.html)
NO (1) NO20045005L (cg-RX-API-DMAC10.html)
NZ (1) NZ536001A (cg-RX-API-DMAC10.html)
RU (1) RU2332220C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003088978A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200408411B (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4949558B2 (ja) 1999-03-23 2012-06-13 ハイバーネーション・セラピューティクス・グローバル・リミテッド 臓器の停止、保護、及び保存
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CN1980946A (zh) * 2004-07-12 2007-06-13 Cv医药有限公司 用于制备a1腺苷受体激动剂的方法
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) * 2004-08-30 2007-11-27 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN104644627A (zh) 2004-09-14 2015-05-27 科罗拉多大学董事会 基于基因靶向使用布新洛尔的治疗方法
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
KR101425579B1 (ko) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 개선된 조직 유지법
WO2008011670A1 (en) 2006-07-25 2008-01-31 Hibernation Therapeutics Limited Trauma therapy
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
ES2397126T3 (es) * 2007-12-21 2013-03-04 Aop Orphan Pharmaceuticals Ag Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 a-2-알파 수용체 길항제와 속도 조절제의 조합물
GB0903299D0 (en) * 2009-02-26 2009-04-08 Guys And St Thomas Nhs Foundat Composition and methods
ES3003038T3 (en) * 2009-03-18 2025-03-10 Incarda Therapeutics Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2011019752A2 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
PT2555776T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
AU2014292827A1 (en) 2013-07-17 2016-02-04 Hibernation Therapeutics, A Kf Llc A method for organ arrest, protection and preservation and reducing tissue injury
WO2015089494A1 (en) * 2013-12-13 2015-06-18 Ankenman Ralph Compositions and methods for treating dysregulated systems
WO2017136421A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CN106370754B (zh) * 2016-11-07 2019-03-08 西安科技大学 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
KR20250171439A (ko) 2019-08-01 2025-12-08 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CA2257948A1 (en) * 1996-06-28 1998-01-08 Merck & Co., Inc. Antiarrhythmic combinations of selective iks antagonists with beta-adenergic blocking agents
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
JP2001509808A (ja) * 1997-01-31 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 多機能性カルシウム/カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
AU4138601A (en) * 1999-12-03 2001-06-12 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
JP2004508336A (ja) * 2000-09-08 2004-03-18 スィーヴィー セラピューティクス インコーポレイテッド 抗不整脈薬としてのプリンリボシド
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker

Similar Documents

Publication Publication Date Title
CN104470939B (zh) 用于肝脏疾病的d型氨基酸化合物
RU2004130826A (ru) Способ лечения аритмии, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
US9416154B2 (en) 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AU2012357940B2 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
JP4021195B2 (ja) 部分もしくは完全a1アゴニスト:n6複素環式5′−チオ置換アデノシン誘導体
CN105085592B (zh) N-[(2`r)-2`-脱氧-2`-氟-2`-甲基-p-苯基-5`-尿苷酰基]-l-丙氨酸1-甲基乙基酯及其制备方法
US9061041B2 (en) 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
AU2011349278B2 (en) Cyclic nucleotide analogs
KR101320008B1 (ko) 3,5-이치환 및 3,5,7-삼치환된-3H-옥사졸로 및3H-티아졸로 〔4,5-d〕피리미딘-2-온 화합물 및 이의전구약물
JP2024514825A (ja) 抗ウイルス剤としてのヌクレオシド及びヌクレオチドアナログ
DK2794628T3 (en) 4'-AZIDO-3'-FLUORO-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
CN108350016B (zh) 抗病毒四氢呋喃衍生物
CN111848711A (zh) 用于hcv感染的2′-氯核苷类似物
TW201418274A (zh) 2’-甲基經取代之核苷衍生物及其用於治療病毒疾病之使用方法
US20140356325A1 (en) Novel 2'-c-methyl nucleoside derivative compounds
CN107108683A (zh) 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
CN102089318B (zh) Hiv抑制剂化合物的盐
CN106536538A (zh) 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物
US20150246068A1 (en) Novel nucleotide prodrug compounds and use
US10899788B2 (en) Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
HK1048821A1 (en) Thiophene a2a receptor agonists
JP2006505525A5 (cg-RX-API-DMAC10.html)
CN101240001B (zh) 2'-氟代核苷
WO2026011167A1 (en) Thionucleosides as antiviral agents
HK1169414B (en) N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production